Memantine (Ebixa) in the later stages of dementia.

Authors
Category Primary study
JournalHospital medicine (London, England : 1998)
Year 2003
Memantine is the first agent licensed for the treatment of moderate to severe Alzheimer's disease. It is an N-methyl D-aspartate (NMDA) receptor antagonist which reduces glutamatergic excitotoxicity. Benefits are seen in cognitive, functional and global measures in both outpatients and nursing home residents. Prospective health economic benefits have been reported.
Epistemonikos ID: 7beddc9448155ccc83cb2f7a00aed46e6429c69f
First added on: May 02, 2023